Transient elevation of NT-proBNP after mRNA COVID-19 vaccination in healthy adults: A longitudinal biomarker analysis

Cardiovascular complications such as myocarditis and pericarditis have been reported following mRNA COVID-19 vaccination, particularly after the second dose. However, little is known about the cardiac biomarker response in otherwise healthy individuals after mRNA COVID-19 vaccination. This study aimed to investigate the dynamics of high-sensitivity cardiac troponins (hs-cTnI, hs-cTnT) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) following mRNA COVID-19 vaccination. We analyzed serum samples collected at multiple time points between April and December 2021 from 83 healthy adult military personnel vaccinated with two doses of mRNA COVID-19 vaccines. Statistical analyses included mixed-effects ANOVA with Geisser-Greenhouse correction and logistic regression to assess the influence of covariates. NT-proBNP levels showed a significant but transient increase, particularly within 14 days after the second vaccine dose (geometric mean 36.2 pg/mL; p < 0.0001). Nearly 49% of participants exhibited a relative increase exceeding 1.5 times their individual baseline. No participant surpassed the 450 pg/mL threshold indicative of cardiovascular complications, and troponin levels remained unchanged across all assessed 14-day intervals. The observed NT-proBNP elevation was not significantly associated with any of the assessed covariates. However, non-significant trends were noted among men, individuals without prior COVID-19 infection or comorbidities, and those vaccinated with the mRNA-1273 (Moderna) vaccine. In healthy adults, mRNA COVID-19 vaccination was associated with a short-term, subclinical elevation in NT-proBNP, particularly after the second dose. While not indicative of overt cardiovascular injury, this biomarker response may reflect transient myocardial stress and warrants further research. • NT-proBNP peaked within 14 days after the second vaccine dose. • No change in hs-cTnI or hs-cTnT levels post vaccination. • Findings suggest short-term myocardial stress without clinical symptoms.

Authors

Institutions

Publication Details

Journal
Vaccine
Published
2026-03-28
DOI
https://doi.org/10.1016/j.vaccine.2026.128535
Primary Topic
Acute Myocardial Infarction Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Transient elevation of NT-proBNP after mRNA COVID-19 vaccination in healthy adults: A longitudinal biomarker analysis

Pavel Dlouhý, I. Lesná, J. Rosina, O Kuchar et al.
Vaccine
Acute Myocardial Infarction Research
article

Transient elevation of NT-proBNP after mRNA COVID-19 vaccination in healthy adults: A longitudinal biomarker analysis

Pavel Dlouhý, I. Lesná, J. Rosina, O Kuchar, Roman Máčalík, Antonin Jabor, M. Petras, Jan Polák, Jan Piťha, Vanda Filová
article en

Abstract

Cardiovascular complications such as myocarditis and pericarditis have been reported following mRNA COVID-19 vaccination, particularly after the second dose. However, little is known about the cardiac biomarker response in otherwise healthy individuals after mRNA COVID-19 vaccination. This study aimed to investigate the dynamics of high-sensitivity cardiac troponins (hs-cTnI, hs-cTnT) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) following mRNA COVID-19 vaccination. We analyzed serum samples collected at multiple time points between April and December 2021 from 83 healthy adult military personnel vaccinated with two doses of mRNA COVID-19 vaccines. Statistical analyses included mixed-effects ANOVA with Geisser-Greenhouse correction and logistic regression to assess the influence of covariates. NT-proBNP levels showed a significant but transient increase, particularly within 14 days after the second vaccine dose (geometric mean 36.2 pg/mL; p < 0.0001). Nearly 49% of participants exhibited a relative increase exceeding 1.5 times their individual baseline. No participant surpassed the 450 pg/mL threshold indicative of cardiovascular complications, and troponin levels remained unchanged across all assessed 14-day intervals. The observed NT-proBNP elevation was not significantly associated with any of the assessed covariates. However, non-significant trends were noted among men, individuals without prior COVID-19 infection or comorbidities, and those vaccinated with the mRNA-1273 (Moderna) vaccine. In healthy adults, mRNA COVID-19 vaccination was associated with a short-term, subclinical elevation in NT-proBNP, particularly after the second dose. While not indicative of overt cardiovascular injury, this biomarker response may reflect transient myocardial stress and warrants further research. • NT-proBNP peaked within 14 days after the second vaccine dose. • No change in hs-cTnI or hs-cTnT levels post vaccination. • Findings suggest short-term myocardial stress without clinical symptoms.

VaccineVol. 80
Charles University (CZ), Fakultní nemocnice Bulovka (CZ), Institute of Clinical and Experimental Medicine (CZ), Institute of Aviation Medicine (CZ), Thomayer University Hospital (CZ), Czech Technical University in Prague (CZ)
Good health and well-being
Openalex Percentile: Top 3%
Acute Myocardial Infarction Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.